Will...'s questions to Myriad Genetics Inc (MYGN) leadership • Q4 2024
Question
Will..., on behalf of Matt Sykes, asked for an update on the progress in the unaffected hereditary cancer market and whether recent market dislocations, such as the LabCorp and Ambry integrations, are creating share gain opportunities.
Answer
Chief Commercial Officer Mark Verratti described the unaffected market as a "sweet spot" for Myriad, driven by its breast cancer risk assessment program and EMR integrations, though he noted workflow conversions take time. CEO Paul Diaz added that while competitor integrations take several quarters to materialize into opportunities, they do present a chance for Myriad to gain share due to its reputation for reliability and consistency.